Quantcast

MedinCell Partners to Address the Untapped Financial Potential in Animal Health   

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News:

MedinCell (Paris:MEDCL) partners with Cornerstone Animal Health to develop a range of best-in-class long-acting injectable veterinary products using MedinCell’s BEPO® proprietary technology.

Cornerstone Animal Health is a US-based Animal Health commercialization group formed by seasoned industry veterans, most of them former executives of iconic companies such as Pfizer Animal Health (Zoetis), Merck Animal Health or Merial. The Cornerstone team has an extensive network, deep experience from regulatory development to successful commercialization of innovative products in Animal Health as well as channel management to get products launched. As independent entrepreneurs, they have also successfully commercialized many products in both the pet market and the food animal market.

Cornerstone will be in charge of funding regulatory development and either license or commercialize the products. The deal is intended to support the financial potential of the BEPO® technology in Animal Health to both accelerate MedinCell’s time to profitability and create sustainable long-term profits. The intended joint-venture deal is structured to limit the impact on MedinCell’s cash and resources.

The first long-acting injectable aims to be a 5-7 days product targeting acute pain for pets and is based on a widely used active ingredient. It is already in lead formulation research and could enter regulatory development in 2020. Additional products should enter lead formulation research in 2020.

Animal Health offers an attractive risk profile as the products can be tested in the target species during the lead formulation selection. There are no human clinical trials, development times are significantly shorter and funding requirements may be one order of magnitude lower compared to human health products.

“Animal Health is another tangible opportunity that we can materialize thanks to the veterans of Cornerstone, stated Christophe Douat, CEO of MedinCell. “We have collaborated with the team in the past and trust them to work with us to develop long-acting products specifically design for animals.”

“Thanks to their convenience, long-acting injectable products should be quickly adopted by veterinaries and pet owners for whom compliance and ease of adoption are challenges”, stated Vince Palasota, CEO of Cornerstone Animal Health. “As an example, our first product in development aims to offer till 7 days of post-surgical or non-surgical pain relief after a single subcutaneous injection made by the veterinarian. No more action is required by the animal owner who has the assurance that his companion receives the proper dosing to ensure adequate pain management.”

About MedinCell

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.

This press release may contain forward-looking statements, especially on the Company’s progress of its clinical trials. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are subject to change without notice, factors beyond the Company’s control and the Company’s financial capabilities.

These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as “objective”, “believe”, “anticipate”, “foresee”, “aim”, “intend”, “may”, “anticipate”, “estimate”, “plan”, “project”, “will”, “may”, “probably”, “should”, “could” and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that may, if any, cause actual results, performance or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (AMF) pursuant to its regulatory obligations, including the Company’s registration document, registered with the AMF on September 4, 2018 under number I. 18-062, as well as in the documents and reports to be published subsequently by the Company. In addition, these forward-looking statements speak only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company’s update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements.

This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company’s shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions. Persons who come to know about this press release are required to inquire about and comply with these restrictions.

Contacts

MedinCell

David Heuzé

Communication leader

[email protected]

+33 (0)6 83 25 21 86

NewCap

Louis-Victor Delouvrier / Alexia Faure

Investor relations

[email protected]

+33 (0)1 44 71 94 94

NewCap

Nicolas Merigeau

Media relations

[email protected]

+33 (0)1 44 71 94 94

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.